View Financial HealthPerrigo 배당 및 자사주 매입배당 기준 점검 4/6Perrigo 은(는) 현재 수익률이 9.8% 인 배당금 지급 회사입니다.핵심 정보9.8%배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률10.4%배당 성장률8.1%다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향-11%최근 배당 및 자사주 매입 업데이트Perrigo Company plc announces Quarterly dividend, payable on June 16, 2026May 01Perrigo Announces Quarterly Dividend, Payable on March 24, 2026Feb 20Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2025Oct 29Perrigo Company plc Declares Quarterly Dividend, Payable on September 16, 2025Jul 31Perrigo Company plc Announces Quarterly Dividend, Payable on June 17, 2025Apr 30Perrigo Company plc Increases Its Quarterly Dividend, Payable on March 25, 2025Feb 20모든 업데이트 보기Recent updatesPerrigo Company plc announces Quarterly dividend, payable on June 16, 2026May 01Perrigo Company plc to Report Q1, 2026 Results on May 06, 2026Apr 22Perrigo Company plc, Annual General Meeting, Apr 30, 2026Mar 23Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2026Feb 26Perrigo Announces Quarterly Dividend, Payable on March 24, 2026Feb 20Perrigo Company plc to Report Q4, 2025 Results on Feb 26, 2026Feb 13Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Perrigo Company plc ShareholdersNov 18Perrigo Company plc Updates Earnings Guidance for the Full Year of 2025Nov 05Perrigo Company plc Declares Quarterly Dividend, Payable on December 16, 2025Oct 29Perrigo Company plc to Report Q3, 2025 Results on Nov 05, 2025Oct 22Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal Year 2025Aug 06Perrigo Company plc Declares Quarterly Dividend, Payable on September 16, 2025Jul 31Perrigo Company plc to Report Q2, 2025 Results on Aug 06, 2025Jul 23KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million.Jul 15Perrigo Company plc Announces Executive ChangesJul 02Perrigo Company plc Announces Executive ChangesJun 05Perrigo Company plc Revises Earnings Guidance for the Fiscal Year 2025May 07+ 1 more updatePerrigo Company plc Announces Quarterly Dividend, Payable on June 17, 2025Apr 30Perrigo Company plc to Report Q1, 2025 Results on May 07, 2025Apr 24Perrigo Company plc, Annual General Meeting, May 01, 2025Mar 12Perrigo Company plc Provides Earnings Targets for the Fiscal Year 2025Feb 28Perrigo Company plc Increases Its Quarterly Dividend, Payable on March 25, 2025Feb 20Perrigo Company plc to Report Q4, 2024 Results on Feb 27, 2025Jan 31Perrigo Company plc Appoints Jonas Samuelson to as A Member of Board of Directors and Audit Committee and the Nominating and Governance CommitteeJan 17Perrigo Company plc Appoints Abbie Lennox as Executive Vice President and Chief Scientific OfficerJan 06Third quarter dividend of US$0.28 announced Nov 11New major risk - Dividend sustainability Nov 07Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023) Nov 07Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024Nov 07Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024Nov 02Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024Oct 23Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and SecretarySep 04Upcoming dividend of US$0.28 per share Aug 26Advisor recently sold €872k worth of stock Aug 23Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital OfficerAug 19Second quarter dividend of US$0.28 announced Aug 12Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023) Aug 04Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024Aug 02+ 2 more updatesPerrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024Jul 20Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.Jul 11Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024Jun 13Perrigo Company plc Announces Executive ChangesMay 30Upcoming dividend of US$0.28 per share May 24Perrigo Company plc Reaffirms Earnings Guidance for 2024May 08+ 1 more updateFirst quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023) May 07Fourth quarter dividend of US$0.28 announced May 06Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024May 01Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.Apr 26Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024Apr 24Perrigo Company plc, Annual General Meeting, May 02, 2024Mar 24Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of DirectorsMar 09Fourth quarter dividend of US$0.28 announced Mar 04Perrigo Company plc Reports Earnings Guidance for the Fiscal Year 2024Feb 29+ 1 more updateFull year 2023 earnings released: US$0.033 loss per share (vs US$0.97 loss in FY 2022) Feb 29Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024Feb 27Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024Feb 14President recently bought €294k worth of stock Nov 23Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023Nov 09Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023Oct 25Perrigo Company plc Announces Executive ChangesSep 12Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023Aug 10Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023Jul 26Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral ContraceptiveJul 14Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive OfficerJun 09+ 1 more updatePerrigo Announces U.S. FDA Approval for Nicotine Coated Mint LozengeMay 17+ 1 more updatePerrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter UseMay 11Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023May 10+ 2 more updatesPerrigo Announces Quarterly Dividend, Payable on June 20, 2023May 05Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023Feb 15Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of DirectorsFeb 10Perrigo Company plc Promotes Alison Ives to Executive Vice President and Chief Scientific OfficerJun 03Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini CapsulesMay 27Perrigo Company plc Announces Retirement of Todd Kingma as Executive Vice President, General Counsel, and Corporate Secretary, Effective August 31, 2022May 13Perrigo Company plc Raises Earnings Guidance for the Fiscal Year 2022May 12+ 2 more updatesPerrigo Company plc Declares Quarterly Dividend, Payable on June 21, 2022May 06Perrigo Company plc Provides Earnings Guidance for the Year 2022Mar 03Perrigo Company plc Announces Quarterly Dividend, Payable on March 17, 2022Feb 17Perrigo Company plc to Report Q4, 2021 Results on Mar 01, 2022Feb 16Perrigo Company plc(TASE:PRGO) dropped from TA-35 IndexFeb 09Perrigo Announces Voluntary Delisting from the Tel Aviv Stock ExchangeNov 24Third quarter 2021 earnings released: US$0.40 loss per share (vs US$1.13 loss in 3Q 2020) Nov 11Perrigo Company plc (NYSE:PRGO) signed a binding offer to acquire HRA Pharma, SA from funds affiliated with Astorg Partners and Goldman Sachs Asset Management, L.P. for transaction value of €1.8 billion.Sep 10Upcoming dividend of US$0.24 per share Aug 26Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.44 profit in 2Q 2020) Aug 12Upcoming dividend of US$0.24 per share May 27First quarter 2021 earnings released: EPS US$0.021 (vs US$0.78 in 1Q 2020) May 12지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: PIG 의 주당 배당금은 지난 10 년 동안 안정적이었습니다.배당금 증가: PIG 의 배당금 지급은 지난 10 년 동안 증가했습니다.배당 수익률 vs 시장Perrigo 배당 수익률 vs 시장PIG의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (PIG)9.8%시장 하위 25% (DE)1.6%시장 상위 25% (DE)4.5%업계 평균 (Pharmaceuticals)2.8%분석가 예측 (PIG) (최대 3년)10.4%주목할만한 배당금: PIG 의 배당금( 9.8% )은 German 시장에서 배당금 지급자의 하위 25%( 1.57% )보다 높습니다.고배당: PIG 의 배당금( 9.8% )은 German 시장( 4.52% )주주 대상 이익 배당수익 보장: PIG 배당금을 지급하고 있지만 회사는 수익성이 없습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 107% )이 높기 때문에 PIG 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YDE 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/30 15:09종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Perrigo Company plc는 32명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jasper HellwegArgus Research CompanyDouglas TsaoBarclaysCharley JonesBarrington Research Associates, Inc.29명의 분석가 더 보기
Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit on Behalf of Perrigo Company plc ShareholdersNov 18
KKR & Co. Inc. (NYSE:KKR) entered into a Master Sale and Purchase Agreement to acquire Aco Hud Nordic AB and Assets related to Dermacosmetics Business of Perrigo Company plc, Perrigo Pharma Holding Nederland BV, and Perrigo Holding NV for approximately €330 million.Jul 15
Perrigo Company plc Appoints Jonas Samuelson to as A Member of Board of Directors and Audit Committee and the Nominating and Governance CommitteeJan 17
Perrigo Company plc Appoints Abbie Lennox as Executive Vice President and Chief Scientific OfficerJan 06
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and SecretarySep 04
Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital OfficerAug 19
Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024Aug 02+ 2 more updates
Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.Jul 11
Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024Jun 13
Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.Apr 26
Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of DirectorsMar 09
Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive OfficerJun 09+ 1 more update
Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of DirectorsFeb 10
Perrigo Company plc Promotes Alison Ives to Executive Vice President and Chief Scientific OfficerJun 03
Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini CapsulesMay 27
Perrigo Company plc Announces Retirement of Todd Kingma as Executive Vice President, General Counsel, and Corporate Secretary, Effective August 31, 2022May 13
Perrigo Company plc (NYSE:PRGO) signed a binding offer to acquire HRA Pharma, SA from funds affiliated with Astorg Partners and Goldman Sachs Asset Management, L.P. for transaction value of €1.8 billion.Sep 10